Tier 3 — preclinical

Alpha-ketoglutarate ameliorates age-related and surgery induced temporomandibular joint osteoarthritis via regulating IKK/NF-κB signaling

Ye X, Li X, Qiu J, Kuang Y, Hua B, Liu X
Aging Cell 2024 23(11):e14269

Bibliography

PubMed
PMID 38992995
PubMed Central
PMC11561675
DOI
10.1111/acel.14269
Funding
Supported by the Guangdong Basic and Applied Basic Research Foundation (2024A1515030015), Innovative Projects with Distinctive Features in Ordinary Universities in Guangdong Province (2023KTSCX017), and the Science Research Cultivation Program of Stomatological Hospital, Southern Medical University (PY2022010).
Competing interests
The authors declared no conflict of interests.

Study snapshot

DesignAged-mouse and surgery-induced rat osteoarthritis study with chondrocyte mechanistic experiments.
ModelMiddle-aged/aged mice, partial-discectomy rat TMJ osteoarthritis and condylar chondrocytes.
SampleMultiple rodent and cell cohorts; group size varied by experiment.
InterventionAKG administration in aged and surgically induced osteoarthritis models.
DurationStudy-specific aging and postoperative protocols.
EndpointsCartilage histology; OARSI score; Chondrogenic markers; Catabolic markers; Cellular senescence; IKK/NF-κB signaling

What the study showed, in plain terms

This Aging Cell study tested AKG against age-related and surgery-induced temporomandibular-joint degeneration.

AKG improved cartilage measures in older mice and in a rat surgical osteoarthritis model and reduced senescence/inflammatory signaling in chondrocytes.

It expands musculoskeletal-aging evidence but does not establish that oral Ca-AKG treats osteoarthritis in people.

Key findings

  • AKG improved condylar-cartilage health in middle-aged and aged mice.
  • Pathology was reduced in a rat partial-discectomy osteoarthritis model.
  • IKK/NF-κB suppression accompanied lower senescence and catabolic markers.

What this study can and cannot tell us

  • Rodent disease models and cell experiments only.
  • TMJ osteoarthritis is a specialized joint model, not direct human osteoporosis evidence.
  • No commercial Ca-AKG formulation or human clinical endpoint was tested.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology